MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up Zacks Equity Research Aug 18, 2026 Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.